Results 191 to 200 of about 39,416 (262)
ABSTRACT Olaparib belongs to the PARP inhibitors and is widely used as an anticancer drug. Due to frequent side effects, it is usually co‐administered with an antihypertensive, such as propranolol and/or an antidiuretic, such as furosemide. In this study, a highly sensitive HPLC‐FLD method was developed for the simultaneous determination of the three ...
Georgios Kamaris +2 more
wiley +1 more source
The neural niche in cancer: mechanistic insights into tumor-neuron-immune crosstalk and therapeutic opportunities. [PDF]
Aysit N +4 more
europepmc +1 more source
Prostaglandin analog therapy challenges and innovation in glaucoma therapeutics. [PDF]
Nath M +4 more
europepmc +1 more source
Current Management of Resistant Hypertension in Patients with Intracerebral Hemorrhage. [PDF]
Nguyen M +4 more
europepmc +1 more source
From gut microbiota metabolism to microvascular injury: Exploring the role and mechanisms of gut microbiota in obesity-induced coronary microcirculation dysfunction. [PDF]
Liu Y +7 more
europepmc +1 more source
The Comparative Effectiveness of PDE5 Inhibitors and β3 Agonists Versus α-Blockers in Medical Expulsive Therapy for Distal Ureteric Stones: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]
Ramanah M +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Heterogeneity of alpha-2 adrenergic receptors
Pharmacology Biochemistry and Behavior, 1985Alpha adrenergic receptors are subdivided into alpha-1 and alpha-2 subtypes on the basis of their pharmacologic properties. An evaluation of data from radioligand binding and functional experiments indicates that the receptors classified as alpha-2 are not a homogeneous group.
D B Bylund
exaly +3 more sources

